Synthetic retinoid fenretinide in breast cancer chemoprevention.

Abstract

Preclinical models suggest that retinoids inhibit mammary carcinogenesis. The induction of apoptosis is a unique feature of fenretinide, the most-studied retinoid in clinical trials of breast cancer chemoprevention, owing to its selective accumulation in breast tissue and its favorable toxicological profile. In a Phase III breast cancer prevention trial, fenretinide showed a strong trend of reduction of incidence of second breast malignancies in premenopausal women, which was confirmed by 15 years of follow-up. This warrants further research on the mechanisms of action and potential efficacy of fenretinide and provides the rationale for a Phase III primary prevention trial in young women at high risk for breast cancer. This review will highlight the role of fenretinide in breast cancer chemoprevention.

• Authors: Bernardo Bonanni, Matteo Lazzeroni, Umberto Veronesi
• Journal: Expert review of anticancer therapy (Expert Rev Anticancer Ther) Vol. 7 Issue 4 Pg. 423-32 (Apr 2007) ISSN: 1744-8328 [Electronic] England
• PMID: 17428163 (Publication Type: Journal Article, Review)

Chemical References

• Retinoids
• Fenretinide

Topics

• Apoptosis (drug effects, physiology)
• Breast Neoplasms (epidemiology, pathology, prevention & control)
• Female
• Fenretinide (chemical synthesis, pharmacology, therapeutic use)
• Humans
• Retinoids (chemical synthesis, pharmacology, therapeutic use)